Contract Research Organization for the Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) Informed the Company ...

Journavx revived an area of development long considered a graveyard. Can any other pain drugs keep investor excitement going?

Baywatch’s Stephen Amell pulled back the curtain on what filming the “very physically challenging” series is really like ...

IMNN-001 is the First and Only frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival benefit in ...

Go’s native fuzzing is useful, but it stands far behind state-of-the-art tooling that the Rust, C, and C++ ecosystems offer with LibAFL and AFL++. Path constraints are hard to solve. Structured inputs ...

First quarter sales increased 12.0% to $230.6 million Achieved first quarter net income of $25.5 million, or $0.67 per ...